Constellation Brands (NYSE: STZ) investors had high hopes heading into its latest earnings update. The alcoholic-beverage giant has been winning market share despite huge demand swings around niches like hard seltzer. Sales trends held up well, especially considering all the volatility around consumer demand right now. Read More...
Motley Fool
Why Oramed Pharmaceuticals Stock Rocketed Higher Today
Shares of the clinical-stage biotech Oramed Pharmaceuticals (NASDAQ: ORMP) were up by a staggering 41.6% as of 3:30 p.m. ET on Friday afternoon. To put this surge in volume into the proper context, the average daily volume for Oramed’s stock over the prior 30-day period has been less than 900,000 shares. Over the last 12 months, Oramed’s stock has attracted short sellers in droves, thanks to the global turmoil in financial markets, the drawdown across clinical-stage biotech stocks, geopolitical unrest, and rising interest rates.
Add Comment